Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R K Pearce

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|August 2, 2001
Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus)E C Maratos, M J Jackson, R K Pearce, et al.
The European Journal of Neuroscience|April 13, 2000
Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPAB Y Zeng, R K Pearce, G M MacKenzie, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|January 1, 1997
Alterations in the distribution of glutathione in the substantia nigra in Parkinson's diseaseR K Pearce, A Owen, S Daniel, et al.
Synapse (New York, N.Y.)|July 1, 1996
Intraventricular infusion of basic fibroblast growth factor (bFGF) in the MPTP-treated common marmosetR K Pearce, P Collins, P Jenner, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 1, 1995
Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus)R K Pearce, M Jackson, L Smith, et al.
Psychopharmacology|April 2, 1999
Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosetsR K Pearce, M Jackson, D R Britton, et al.
Clinical Neuropharmacology|July 15, 2000
Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmosetL A Smith, M G Jackson, C Bonhomme, et al.
Experimental Brain Research|September 1, 2000
Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmosetP Jenner, B Y Zeng, L A Smith, et al.
The European Journal of Neuroscience|February 13, 2001
GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosetsM M Iravani, S Costa, M J Jackson, et al.
Experimental Neurology|March 31, 2000
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeysT Kanda, M J Jackson, L A Smith, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Movement Disorders : Official Journal of the Movement Disorder Society|August 2, 2001
Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus)E C Maratos, M J Jackson, R K Pearce, et al.
The European Journal of Neuroscience|April 13, 2000
Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPAB Y Zeng, R K Pearce, G M MacKenzie, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|January 1, 1997
Alterations in the distribution of glutathione in the substantia nigra in Parkinson's diseaseR K Pearce, A Owen, S Daniel, et al.
Synapse (New York, N.Y.)|July 1, 1996
Intraventricular infusion of basic fibroblast growth factor (bFGF) in the MPTP-treated common marmosetR K Pearce, P Collins, P Jenner, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 1, 1995
Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus)R K Pearce, M Jackson, L Smith, et al.
Psychopharmacology|April 2, 1999
Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosetsR K Pearce, M Jackson, D R Britton, et al.
Clinical Neuropharmacology|July 15, 2000
Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmosetL A Smith, M G Jackson, C Bonhomme, et al.
Experimental Brain Research|September 1, 2000
Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmosetP Jenner, B Y Zeng, L A Smith, et al.
The European Journal of Neuroscience|February 13, 2001
GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosetsM M Iravani, S Costa, M J Jackson, et al.
Experimental Neurology|March 31, 2000
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeysT Kanda, M J Jackson, L A Smith, et al.
Pageof 4